Key Research Areas for FOXO4-DRI FOXO4p53 protein-protein interaction disruption assays co-immunoprecipitation (CO-IP) and competitive binding studies Senescent cell identification and selective elimination assays SA--galactosidase, p16, p21, p53 staining combined with FOXO4-DRI apoptosis induction p53 TAD2 binding, nuclear exclusion, and mitochondrial translocation studies phospho-p53 (Ser15) pathway research BAX/BCL-2/Caspase-3 intrinsic apoptosis pathway investigations in senescent cell models SASP (Senescence-Associated Secretory Phenotype) characterisation and suppression IL-6, IL-8, MMP, VEGF, CXCL2/3 pathway studies Tissue-specific senescent cell biology fibroblasts, endothelial cells, Leydig cells, chondrocytes, epithelial cells Vascular ageing pathway research endothelial cell senescence, aortic function, and ROS/oxidative stress studies Senescent Leydig cell and male reproductive ageing models FOXO4 nuclear translocation and testosterone synthesis pathway research Chondrocyte senescence and cartilage biology senescent cell removal and chondrogenic potential restoration studies Keloid and pathological scar biology senescent fibroblast elimination and SASP suppression in fibrotic tissue models Senescent cancer cell elimination FOXO4-DRI as a senolytic tool in oncology research models Comparative senolytic research FOXO4-DRI vs
[57] Approval of the original brand-name versions (such as Ozempic) was based on a biologic (recombinant DNA) production process using a genetically-modified yeast ( Saccharomyces cerevisiae ) to produce a precursor to semaglutide, and subsequent chemical processes (protein purification) to create the active ingredient
Lyophilization, or freeze-drying, significantly extends the shelf life of the peptide by removing water, which inhibits hydrolysis and microbial growth
-y et al
Nadjarzadeh A, Shidfar F, Amirjannati N, et al
